UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ____)*

INTRA-CELLULAR THERAPIES, INC.

(Name of Issuer)					
Common Stock					
(Title of Class of Securities)					
46116X101					
(CUSIP Number)					
September 30, 2024					
(Date of Event Which Requires Filing of this Statement)					
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:					
⊠ Rule 13d-1(b)					
□ Rule 13d-1(c)					
□ Rule 13d-1(d)					
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.					
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).					

No.	46116	5X101					
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) JPMORGAN CHASE & CO. 13-2624428						
			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
2	(a) □ (b) □						
	SEC US	E ONL	Y				
3							
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Delawar	e	SOLE VOTING POWER				
		_	SOLE VOTINGTOWER				
		5	4,943,665				
			SHARED VOTING POWER				
		6					
	BER OF		SOLE DISPOSITIVE POWER				
SHARES BENEFICIALLY		7	5,287,819				
OWNED BY EACH			SHARED DISPOSITIVE POWER				
REPO	RTING	8	39				
FERSOI	SON WITH: 39 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
9							
9	5,296,395 CHECK IF THE ACCREGATE AMOUNT IN DOW (1) EVOLUTIES CERTAIN SHARES (SEE INSTRUCTIONS)						
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
10							
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
11	5.0 %						
	ТҮРЕ О	F REP	ORTING PERSON (SEE INSTRUCTIONS)				
12	НС						

FOOTNOTES

Item 1.							
	(a)	Name o	f Issuer -CELLULAR THERAPIES, INC.				
	(b)	430 Eas	s of Issuer's Principal Executive Offices tt 29th Street, ork, New York 10016				
Item 2.							
	(a)		f Person Filing GAN CHASE & CO.				
	(b)	383 Ma	s of Principal Business Office or, if none, Residence dison Avenue ork, NY 10179				
	(c)	Citizens Delawar					
	(d)	Title of Class of Securities Common Stock					
	(e)	CUSIP Number 46116X101					
Item 3.	If this s	tatement	t is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:				
	(a)	_	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).				
	(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).				
	(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).				
	(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).				
	(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);				
	(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);				
	(g)	X	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);				
	(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);				
	(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Compan Act of 1940 (15 U.S.C. 80a-3);				
	(i)	П	A non-U.S. institution in accordance with 8 240 13d-1(b)(1)(ii)(1)				

(k)	A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii) (J), please specify the type of institution:

Item 4. Ownership.

ovide the following information re	1' /1	, 1 1	C.1	1 0		1	1 4.0 1.	T, 1
avide the fallowing information re	egarding the aggre	gate number and	nercentage of th	e class of	securities of 1	he icciier i	dentitied in	Item I

- (a) Amount beneficially owned: 5,296,395
- (b) Percent of class: 5.0 %
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 4,943,665
 - (ii) Shared power to vote or to direct the vote: 0
 - (iii) Sole power to dispose or to direct the disposition of: 5,287,819
 - (iv) Shared power to dispose or to direct the disposition of: 39

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

J.P. Morgan Trust Company of Delaware

J.P. Morgan Securities LLC

JPMorgan Chase Bank, National Association

JPMorgan Asset Management (Asia Pacific) Limited

JPMorgan Asset Management (UK) Limited

J.P. Morgan Investment Management Inc.

J.P. Morgan Private Wealth Advisors LLC

55I, LLC

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item Certification 10.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JPMORGAN CHASE & CO.

Date: October 10, 2024 By: /s/ Rachel Tsvaygoft

Name: Rachel Tsvaygoft Title: Vice President

Footnotes:

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)